IL150289A0 - Drug combination for the treatment of depression and related disorders comprising mirtazapine - Google Patents

Drug combination for the treatment of depression and related disorders comprising mirtazapine

Info

Publication number
IL150289A0
IL150289A0 IL15028901A IL15028901A IL150289A0 IL 150289 A0 IL150289 A0 IL 150289A0 IL 15028901 A IL15028901 A IL 15028901A IL 15028901 A IL15028901 A IL 15028901A IL 150289 A0 IL150289 A0 IL 150289A0
Authority
IL
Israel
Prior art keywords
mirtazapine
depression
treatment
related disorders
drug combination
Prior art date
Application number
IL15028901A
Other languages
English (en)
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of IL150289A0 publication Critical patent/IL150289A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL15028901A 2000-01-19 2001-01-15 Drug combination for the treatment of depression and related disorders comprising mirtazapine IL150289A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00200189 2000-01-19
PCT/EP2001/000407 WO2001052855A2 (en) 2000-01-19 2001-01-15 Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone

Publications (1)

Publication Number Publication Date
IL150289A0 true IL150289A0 (en) 2002-12-01

Family

ID=8170928

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15028901A IL150289A0 (en) 2000-01-19 2001-01-15 Drug combination for the treatment of depression and related disorders comprising mirtazapine

Country Status (21)

Country Link
US (2) US6835728B2 (xx)
EP (1) EP1251854A2 (xx)
JP (1) JP2003520237A (xx)
KR (1) KR20020068404A (xx)
CN (1) CN1223349C (xx)
AR (1) AR027240A1 (xx)
AU (1) AU780817B2 (xx)
BR (1) BR0107721A (xx)
CA (1) CA2396066A1 (xx)
CO (1) CO5261583A1 (xx)
HK (1) HK1047548A1 (xx)
HU (1) HUP0204050A3 (xx)
IL (1) IL150289A0 (xx)
MX (1) MXPA02007095A (xx)
NO (1) NO20023448L (xx)
PE (1) PE20011049A1 (xx)
PL (1) PL356605A1 (xx)
RU (1) RU2268725C2 (xx)
SK (1) SK10552002A3 (xx)
WO (1) WO2001052855A2 (xx)
ZA (1) ZA200205161B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20060039867A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders with setiptiline
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
TW200800306A (en) 2005-09-12 2008-01-01 Wyeth Corp Sustained-release formulation and uses thereof
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
EP1792618A1 (en) * 2005-11-30 2007-06-06 Rainer Freynhagen R-mirtazapine for the treatment of pain
TW200808804A (en) * 2006-05-22 2008-02-16 Organon Nv Mirtazapine for the treatment of neuropathic pain
KR20090024140A (ko) * 2006-05-22 2009-03-06 반다 파마슈티칼즈, 인코퍼레이티드. 우울증 질환에 대한 치료
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
KR20100094495A (ko) * 2007-11-02 2010-08-26 애크럭스 디디에스 피티와이 리미티드 호르몬 및 스테로이드를 위한 경피 전달 시스템
US20130064770A1 (en) 2010-05-28 2013-03-14 Ge Healthcare Limited Radiolabeled compounds and methods thereof
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
CN108743593B (zh) * 2018-08-31 2019-03-26 程世宏 一种抗抑郁药物及其口服颗粒剂和制药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
US4423049A (en) * 1981-12-28 1983-12-27 Mead Johnson & Company 2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4771053A (en) * 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5011841B1 (en) * 1989-11-14 1994-09-06 Pfizer Treatment of depression
GB9303968D0 (en) 1993-02-26 1993-04-14 Wyeth John & Brother Ltd 5-ht1a ligands
GB9603136D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ZA982368B (en) * 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent

Also Published As

Publication number Publication date
CA2396066A1 (en) 2001-07-26
NO20023448D0 (no) 2002-07-18
WO2001052855A3 (en) 2002-01-10
SK10552002A3 (sk) 2002-12-03
KR20020068404A (ko) 2002-08-27
HK1047548A1 (zh) 2003-02-28
AR027240A1 (es) 2003-03-19
AU2516201A (en) 2001-07-31
PL356605A1 (en) 2004-06-28
BR0107721A (pt) 2002-10-01
NO20023448L (no) 2002-09-17
CO5261583A1 (es) 2003-03-31
AU780817B2 (en) 2005-04-21
US20050090488A1 (en) 2005-04-28
MXPA02007095A (es) 2003-04-14
ZA200205161B (en) 2003-09-29
US6835728B2 (en) 2004-12-28
US20030105083A1 (en) 2003-06-05
EP1251854A2 (en) 2002-10-30
PE20011049A1 (es) 2001-10-18
WO2001052855A2 (en) 2001-07-26
HUP0204050A2 (hu) 2003-03-28
RU2002122084A (ru) 2004-03-10
HUP0204050A3 (en) 2004-09-28
JP2003520237A (ja) 2003-07-02
WO2001052855A8 (en) 2002-12-27
CN1223349C (zh) 2005-10-19
CN1395486A (zh) 2003-02-05
RU2268725C2 (ru) 2006-01-27

Similar Documents

Publication Publication Date Title
GB0007193D0 (en) Treatment of movrmrnt disorders
IL196301A0 (en) Medicament for the treatment of hapatitis c
EP1367060A4 (en) GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND THEIR MEDICAL USE
EP1364957A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND THEIR MEDICAL USE
EP1364958A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF
HK1152243A1 (en) Vegf for use in the treatment of central nervous system disorders vegf
IL155795A0 (en) Combination of drugs (e.g. chlorpromazine and pentamidine) for the treatment of neoplastic disorders
IL151890A0 (en) Hydroxyphenyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
IL161267A0 (en) Combinations for the treatment of immunoinflammatory disorders
IL150289A0 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
AU4541101A (en) Design and discovery of protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
GB0004531D0 (en) The treatment of respiratory diseases
IL151891A0 (en) Quinolinyl-piperidin 4-ylidene-methyl-benzamide derivatives for the treatment of pain
IL151765A0 (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain
GB0001710D0 (en) Therapeutic treatment
HK1049122A1 (en) The use of mirtazapine for the treatment of sleep disorders
HUP0301553A3 (en) Pharmaceutical compositions and their use for treating neurological disorders
MXPA03004190A (es) Tratamiento de trastornos de ansiedad.
PL351554A1 (en) Osanetant in the treatment of mood disorders
AU2096002A (en) Therapeutic treatment
IL151493A0 (en) Use of dermaciclane for the treatment of anxiety and depression
IL149705A0 (en) Combination treatment for depression and anxiety
IL153788A0 (en) Treatment of eating disorders using carboxyalkylethers
GB0021927D0 (en) Use of pharmaceutical combination